Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.
William V. Padula, PhD
Advertisement
Articles by William V. Padula, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
4
Improving Access and Care for All Patients With Atopic Dermatitis
5
